Next-Gen mRNA flu shot passes first safety test in humans
NCT ID NCT06125691
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This early-stage study tested a new type of seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially boost immune responses. Researchers gave the vaccine to 139 healthy adults aged 18-49 and 65-85 to check for side effects and measure antibody levels. The goal was to find the safest and most effective dose before moving to larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emeritus Research Camberwell
Melbourne, Victoria, 3124, Australia
-
Nucleus Network Brisbane Clinic
Brisbane, Queensland, Australia
Conditions
Explore the condition pages connected to this study.